CDC’s Mission on IBD
We work to understand the epidemiology of inflammatory bowel disease (IBD) to effectively target interventions and inform best clinical practices by:
- Gathering national prevalence and incidence data.
- Supporting population-based studies to describe demographic and clinical characteristics of people with IBD and to assess the impact of the disease and various clinical practices in managing IBD.
- Adapting and expanding current studies to capture socio-economic, racial, and geographic differences among the population.
- Build a registry of patients with incident diagnosis of CD and UC by leveraging the existing infrastructure of two highly successful pediatric and adult research networks.
- Estimate the incidence and prevalence of CD and UC at a national level using representative data that encompasses populations from all segments of the socioeconomic and geographic distribution of the United States.
- Determine whether race and IBD practice volume are associated with patterns of care and key outcomes including use of biologics, steroids, narcotics, hospitalization, and surgery at a national level and within high volume IBD centers.
- Selected Publications.1
- Develop and implement a prototype for a national surveillance system to collect estimates of the incidence and prevalence of IBD in the US.
- Determine the impact of IBD on affected persons.
- Identify psychosocial, economic, demographic, clinical, and biological variables associated with disparate outcomes in IBD.
- Develop programs to address variations in clinical practice that are associated with disparate outcomes in IBD in order to improve disease outcomes.
- Selected publications.2-7
- More than 2.6 million cases of provider-diagnosed inflammatory bowel disease in the United States. Digestive Disease Week. 2022; abstract, San Diego, CA.
- Shapiro JM, Zoega H, Shah SA, Bright RM. Incidence of Crohn’s disease and ulcerative colitis in Rhode Island: report from the Ocean State Crohn’s and Colitis Area Registry. Inflamm Bowel Dis. 2016;22(6):1456‒1461.
- Shmidt E, Suárez-Fariñas M, Mallette M et al. Erectile Dysfunction is highly prevalent in men with newly diagnosed inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(8):1408‒1416. doi: 10.1093/ibd/izy401.
- Shmidt E, Suárez-Fariñas M, Mallette M et al. A longitudinal study of sexual function in women with newly diagnosed inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(7):1262‒1270. doi: 10.1093/ibd/izy397.
- Cohen BL, Zoega H, Shah SA et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther. 2014;39(8):811‒822. doi: 10.1111/apt.12659.
- Shapiro JM, Hagin SE, Shah SA, et al. Corticosteroid use in a prospective, community-based cohort of newly diagnosed inflammatory bowel disease patients. Dig Dis Sci. 2016;61(6):1635‒1640. doi: 10.1007/s10620-015-4010-4.
- Shapiro JM, de Zoete MR, Palm NW et al. Immunoglobulin a targets a unique subset of the Microbiota in inflammatory bowel disease. Cell Host Microbe. 2021;29(1):83‒93.e3. doi: 10.1016/j.chom.2020.12.003.
Page last reviewed: April 14, 2022